Product

Brands

Products

Health Solutions

Alere Triage® NGAL Test

Alere Triage NGAL Test

The Alere Triage® NGAL Test is a point-of-care* fluorescence immunoassay for the rapid, quantitative determination of Neutrophil Gelantinase-Associated Lipocalin (NGAL). Studies have shown that NGAL levels can provide early information regarding the risk of AKI development.1 CE Marked. (Not available in the USA)

For use with the Alere Triage® MeterPro.

Benefits

  • The possibility of improved patient outcomes through differential diagnosis and early AKI intervention

  • Clinical studies* show that NGAL elevates in association with AKI and correlates with AKI severity

  • Provides a quantitative result in approximately 15 minutes at the point of care or in the clinical lab

  • Requires no sample processing, precision pipetting, or daily liquid controls

 

Show more

Specifications

  • For use with Alere Triage® Meters

  • Yields results in about 15 minutes

  • Uses EDTA anti-coagulated plasma or whole blood sample types.

Show more

References

1. De Geus et al. Neutrophil gelatinase associated lipocalin at ICU admission predicts for acute kidney injury in adult patients. AJRCCM Articles in Press. October 8, 2010as doi:10.1164/rccm.200908-1214OC.

Constantin, JM et al. Plasma NGAL is an early marker of acute kidney injury (AKI) in adult critically ill patients: A prospective study. Journal of Critical Care. doi:10.1016/j.jcrc.2009.05.010.

Cruz, D et al. Plasma neutrophil gelatinase-associated lipocalin is an early biomarker for acute kidney injury in an adult ICU population. Intensive Care Med. doi: 10.1007/s00134-009-1711-1.

*Available for laboratory use only in Canada

Show more

Technical Support

By telephone
1-877-308-8287

By email
Contact Form

Alere™ Home Monitoring & Alere INRatio®2 System

Alere Home Monitoring & Alere INRatio SystemAlere is the leading provider of home monitoring services for individuals on warfarin. Home INR monitoring has been clinically proven to increase patients’ time in therapeutic range by encouraging more frequent testing. In fact, 85% of patients stay within their therapeutic range when monitored weekly. With the Alere INRatio®2 Monitor, patients can test easily from the comfort of home and obtain accurate results in 60 seconds. Doctors, meanwhile, can focus on treating higher-risk patients and prevent more serious events.

Learn More